Antipsychotic Use Doesn't Up Congenital Malformations

This article originally appeared here.
Share this content:
Antipsychotic Use Doesn't Up Congenital Malformations
Antipsychotic Use Doesn't Up Congenital Malformations

WEDNESDAY, Aug. 17, 2016 (HealthDay News) -- Use of antipsychotics (APs) in pregnancy does not appear to increase the risk for congenital malformations, according to a study published online Aug. 17 in JAMA Psychiatry.

Krista F. Huybrechts, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues examined the risk for congenital malformations and cardiac malformations associated with exposure to APs in the first trimester in a sample of 1,341,715 pregnancies.

The researchers found that 0.69 and 0.05 percent of women filled at least one prescription for an atypical AP and filled at least one prescription for a typical AP during the first trimester, respectively. Congenital malformations were diagnosed in 32.7 per 1,000 births not exposed to APs, compared with 44.5 and 38.2 per 1,000 births exposed to atypical and typical APs, respectively. For atypical APs there was an increased risk for malformations in unadjusted analyses (relative risk [RR], 1.36; 95 percent confidence interval [CI], 1.24 to 1.50), but not for typical APs (RR, 1.17; 95 percent CI, 0.81 to 1.68). After adjustment for confounding variables, the RRs were reduced for atypical APs (1.05; 95 percent CI, 0.96 to 1.16) and for typical APs (0.90; 95 percent CI, 0.62 to 1.31). Similar findings were seen for cardiac malformations.

"Evidence from this large study suggests that use of APs early in pregnancy generally does not meaningfully increase the risk for congenital malformations overall or cardiac malformations in particular," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Post-Deployment Screening Has Limited Benefit in U.K. Military

Post-Deployment Screening Has Limited Benefit in U.K. Military

Screening based on tailored advice does not reduce prevalence of disorders or increase help-seeking

Excess BMI Ups Risk of T1DM in Autoantibody-Positive Relatives

Excess BMI Ups Risk of T1DM in Autoantibody-Positive ...

Increased diabetes progression risk occurred at lower cumulative excess BMI index in children <12

Baricitinib Associated With Significant Improvement in RA

Baricitinib Associated With Significant Improvement in RA

Findings versus placebo, adalimumab in patients non-responsive to methotrexate

is free, fast, and customized just for you!

Already a member?

Sign In Now »